Eli Lilly announced an agreement to acquire Centessa Pharmaceuticals for $38.00 in cash per share plus one non‑transferrable CVR, sending Centessa shares up about 45% in Tuesday morning trading. The deal represents a significant takeover premium for Centessa and is material to the company and its shareholders; terms include a cash component and a CVR (details in article truncated).
Eli Lilly announced an agreement to acquire Centessa Pharmaceuticals for $38.00 in cash per share plus one non‑transferrable CVR, sending Centessa shares up about 45% in Tuesday morning trading. The deal represents a significant takeover premium for Centessa and is material to the company and its shareholders; terms include a cash component and a CVR (details in article truncated).
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.75
Ticker Sentiment
